Sun Pharma Inks $55.5M Psoriasis Deal

Jul 06, 2017

India's Sun Pharmaceutical has signed a longterm agreement with South Korean CMO Samsung BioLogics for the manufacture of an experimental psoriasis treatment.

The novel investigational biologic, known as tildrakizumab, is currently under review by the US FDA and the European Medicines Agency (EMA). 

Sun Pharma's subsidiary received worldwide rights to tildrakizumab from Merck (through a Merck subsidiary), known as MSD outside the United States and Canada, in 2014.

Read the press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments